Solis Women's Health Names Mano Mahadeva CFO
Solis Women's Health Names Mano Mahadeva CFO
ADDISON, TX -- (Marketwire) -- 01/25/13 -- Solis Women's Health, the nation's largest independent provider of screening and diagnostics for breast cancer, is pleased to announce that Mano Mahadeva, CPA, has been appointed Chief Financial Officer (CFO).
Mr. Mahadeva will provide strategic operational planning support as well as daily financial accountability, management and reporting as Solis Women's Health continues to expand its nationwide network of clinics devoted exclusively to the screening and diagnosis of breast cancer, which currently serves over 500,000 patients in five states.
"Mano has a strong track record of successfully driving growth through sound fiscal planning and responsible financial management in multi-location, alternative site (non-hospital) healthcare companies," said Solis Chairman Matthew Witte. "We look forward to the addition of his proven leadership skills as we continue to expand our platform in existing and new markets with a particular focus on partnering with major hospital systems in improving their continuum of care in women's health."
Prior to assuming the position of CFO at Solis, Mr. Mahadeva was the Executive Director, North Texas Region, for U.S. Oncology Network, a $3.6B division of Fortune 15 McKesson Corporation. Under Mr. Mahadeva's leadership, the division grew from $300M to $360M in annual revenue in the last five years, boasting a 25.4% profit margin. In his 13 years at U.S. Oncology, Mr. Mahadeva also held the positions of Regional Finance Director and Director, Corporate Financial Planning. He has extensive experience in valuation and investor relations, spearheading financial modeling and analysis projects resulting in successful joint ventures with hospitals and other partners. In addition, Mr. Mahadeva puts a priority on internal and external client satisfaction as an indicator of overall business health, and he is adept at deploying Lean Six Sigma as a key driver behind business process initiatives. Prior to U.S. Oncology, Mr. Mahadeva held positions of financial responsibility at Physician Reliance Network, Texas Orthopedic Associates and Associated Orthopedics and Sports Medicine, all in Texas.
Mr. Mahadeva holds a Bachelor in Accounting from University of Te xas, Dallas, and an MBA in Management from Texas A&M University - Commerce. He is a CPA, and holds ABV, CIA, CrFA, CGMA, CFF, CTP, CITP, LREB, CFA (Level 3 Candidate), CMA, and CFM credentials.
"Mano has a keen ability to understand and influence both the business and financial needs of a growing company like ours," said Solis CEO, James Polfreman. "His proven ability to work through the challenges of acquisitions while never losing sight of service quality nor revenue goals was a key factor in bringing Mano on board. We will rely on Mano to help us more efficiently and effectively meet our goals by allowing us to measure and gauge our performance with detail we did not previously possess. We look forward to having him on our team as we continue to offer exceptional breast care to women nationwide."
With evidence that annual mammograms are effective in detecting breast cancer in its earliest stages, Solis Women's Health was established to provide the highest standard of care and services in a positive atmosphere. The company was founded on the premise that by focusing exclusively on the detection of breast cancer, employing only experienced fellowship-trained breast physicians and utilizing state-of-the-art digital equipment, it can produce significantly better outcomes.
ABOUT SOLIS WOMEN'S HEALTH
Solis Women's Health is a specialized healthcare provider focused exclusively on the screening and diagnosis of breast cancer. Headquartered in Addison, Texas, Solis currently operates 20 clinics in Dallas, Ft. Worth, Phoenix, Indianapolis, Columbus, Ohio; and Greensboro, N.C. Solis provides a complete range of breast health services including screening and diagnostic mammography, computer-aided detection, breast ultrasound, automated breast ultrasound, bone densitometry, stereotactic and ultrasound-guided biopsy, breast specific gamma imaging and breast MRI. For more information, visit www.SolisHealth.com.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2210843
Gregory M. Scott Vice President, Business Development Solis Women's Health Office: 469.398.4107 email@example.com